Catalyst
Slingshot members are tracking this event:
Genfit Phase 2 study testing ELAFIBRANOR (GFT505) in primary biliary cirrhosis (PBC) expecting to enroll first patient in Q2 2017
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 05, 2017
Occurred Source:
http://www.genfit.com/press-release/genfit-first-patient-enrolled-phase-2-trial-recruiting-adults-primary-biliary-cholangitis-pbc-rare-liver-disease/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Elafibranor, Gft505, Phase 2, Primary Biliary Cirrhosis